Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Intranasal delivery of extracellular vesicles: A promising new approach for treating neurological and respiratory disorders.
J Control Release
January 2025
Drug Delivery Laboratory, Departamento de Ciencias y Tecnología Farmacéuticas, Universidad de Chile, Santiago, Chile; Advanced Center for Chronic Diseases (ACCDiS), Santiago, Chile; Center of New Drugs for Hypertension and Heart Failure (CENDHY), Santiago, Chile. Electronic address:
Background: Extracellular vesicles (EVs) are membrane vesicles secreted by all types of cells, including bacteria, animals, and plants. These vesicles contain proteins, nucleic acids, and lipids from their parent cells and can transfer these components between cells. EVs have attracted attention for their potential use in diagnosis and therapy due to their natural properties, such as low immunogenicity, high biocompatibility, and ability to cross the blood-brain barrier.
View Article and Find Full Text PDFConsequences of Recurrent Hyperkalemia on Cardiovascular Outcomes and Mortality.
JACC Adv
November 2024
AstraZeneca, Wilmington, Delaware, USA.
Article Synopsis
- Recurrent hyperkalemia (HK) in patients with chronic kidney disease (CKD) is linked to significantly higher risks of all-cause mortality and cardiovascular (CV) issues compared to patients with normal potassium levels.
- The study involved matching 6,337 patients with recurrent HK to those with normokalemia, adjusting for relevant factors, to ensure a fair comparison.
- Findings indicated that recurrent HK is particularly detrimental, increasing risks for major adverse cardiovascular events (MACE+) and hospitalizations due to arrhythmias, affecting both the overall CKD population and those with co-occurring heart failure.
Right ventricular stroke work index from echocardiography in patients with pulmonary arterial hypertension-the role in short-term follow-up assessment.
Eur Heart J Imaging Methods Pract
July 2024
Department of Clinical Sciences Lund, Clinical Physiology, Lund University, Skane University Hospital, Entrégatan, Lund 221 85, Sweden.
Aims: Right ventricular (RV) failure causes high mortality in patients with pulmonary arterial hypertension (PAH). RV stroke work index (RVSWi) poses as a potential predictor of outcome. We evaluated how RVSWi by echocardiography (ECHO) or right heart catheterization (RHC) is altered following PAH treatment and if RVSWi is an indicator of outcome in PAH.
View Article and Find Full Text PDFResolution of Fenfluramine-associated pulmonary arterial hypertension in Lennox-Gastaut syndrome: A case report and literature review.
Epilepsy Behav Rep
November 2024
Department of Pediatric Neurology, Boston Children's Health Physicians, Valhalla, NY 10532, USA.
Fenfluramine is a medication originally approved for weight loss before being withdrawn for an association with the development of pulmonary arterial hypertension (PAH) and cardiac valvulopathy. Interest in fenfluramine at lower doses has re-emerged for treatment of drug-resistant epilepsy (DRE). Here, we present a case of a patient with Lennox-Gastaut Syndrome (LGS) treated with fenfluramine with development of PAH and tricuspid regurgitation that resolved upon discontinuation.
View Article and Find Full Text PDFHigher blood pressure targets for hypertension in older adults.
Cochrane Database Syst Rev
December 2024
Department of Family Medicine, University of Alberta, Edmonton, Canada.
Background: This is an update of the original Cochrane review, published in 2017. Eight out of 10 major antihypertensive trials in adults, 65 years of age or older, attempted to achieve a target systolic blood pressure (BP) of < 160 mmHg. Collectively, these trials demonstrated cardiovascular benefit for treatment, compared to no treatment, for older adults with BP > 160 mmHg.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!